LakeShore Biopharma Co (LakeShore Biopharma Co) NonCurrent Deferred Liabilities : $3.08 Mil (As of Sep. 2023)

View and export this data going back to 2023. Start your Free Trial

What is LakeShore Biopharma Co NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

LakeShore Biopharma Co's non-current deferred liabilities for the quarter that ended in Sep. 2023 was $3.08 Mil.

LakeShore Biopharma Co NonCurrent Deferred Liabilities Historical Data

The historical data trend for LakeShore Biopharma Co's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LakeShore Biopharma Co NonCurrent Deferred Liabilities Chart

LakeShore Biopharma Co Annual Data

Trend

Mar21

Mar22

Mar23

NonCurrent Deferred Liabilities

4.74

3.43

LakeShore Biopharma Co Semi-Annual Data
	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
NonCurrent Deferred Liabilities	Get a 7-Day Free Trial			-	4.74	2.97	3.43	3.08

LakeShore Biopharma Co NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of LakeShore Biopharma Co's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

LakeShore Biopharma Co (LakeShore Biopharma Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » NonCurrent Deferred Liabilities

Comparable Companies

Traded in Other Exchanges

H6Z:Germany

Address

38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629

Website

https://www.yishengbio.com

YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminium-free lyophilized rabies vaccine that was launched in China. It has one operating segment, which is the development, production, marketing and sale of biopharmaceutical products.